In the News
GNS Healthcare, MMRF Bring Patient Simulations to Multiple Myeloma Precision Treatment, Trial Design
Precision Oncology News reporter discusses Gemini and its prospective impact on multiple myeloma. Read more here.
read more
GNS Healthcare Launches Computer Model of Disease Progression, Treatment Responses in Myeloma
Myeloma Research News covers GNS launch of Gemini. Read more here.
read more
Wall Street Journal Covers GNS Launch of Gemini
This is the first AI-based virtual patient for multiple myeloma, said Colin Hill, the Cambridge, Mass.-based company’s co-founder and chief executive. It is traditionally difficult to predict how specific drugs or combinations of drugs might help individual multiple...
read moreEvents
Colin Hill to Speak at 2020 STAT Health Tech Summit
This year’s 2020 STAT Health Tech Summit will engage industry leaders, from giants like Apple and Google to upstarts emerging from stealth to discuss how breakthroughs in health and medicine are not just biological – they are technological. The two-day event will...
read more
Colin Hill to Speak at MassBio’s State of Possible Conference
This year’s State of Possible Conference, MassBio's Annual Meeting, will celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate...
read more
Iya Khalil to Weigh in on How AI is Transforming Early-Stage Biotech Partnerships and Drug Discovery
Artificial Intelligence (AI) and Machine Learning (ML) are rapidly transforming industries, from autonomous cars, to logistics, to technology – and now biotechnology. Excitement about AI and ML driven solutions for accelerated drug discovery, drug development, and...
read morePress Releases
QIAGEN Adopts GNS Healthcare’s Gemini – The in silico Patient™ Across Multiple Cancers
Partnership enables enhanced capability to discover new targets and prognostic markers Somerville, MA: GNS Healthcare, the leading AI-driven precision medicine company, today announced a partnership with QIAGEN, the leading global provider of Sample to Insight...
read moreGNS Healthcare Presents Novel Use of AI to Identify Drivers of Response to Immune Checkpoint Inhibitor Therapy
AI-driven in silico patients used to accurately identify types of immune responses in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC). CAMBRIDGE, Mass.– [July 21, 2020] – GNS Healthcare (GNS), a leading AI and simulation company,...
read moreGNS Healthcare Launches Gemini, the First In Silico Patient for Multiple Myeloma
A transformative innovation GeminiTM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma GNS Healthcare, an AI-driven precision medicine company, today announced the launch of...
read more